WEMADE PRESENTS NEW BATTLEFIELD 'SNOWFIELD AREA' IN MIR4

 

MIR4 New Battlefield ‘Snowfield Area’ opened (Graphic: Wemade) 

Snowfield Area and new main quests released
Max. Level for Character, Constitution, and Inner Force increased
New Legendary Party Leader Spirit, Small White Dragon Chunryu, shares its skill effects with party members

SEOUL, South Korea, Jan 27 (Bernama-BUSINESS WIRE) -- Wemade’s blockbuster mobile MMORPG MIR4 released a new battlefield, Snowfield Area, on January 26th.
 

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230126005414/en/ 

Snowfield Area is divided into 5 parts: Nine Dragon Ice Field, Nine Dragon Ice Palace, Nine Dragon Labyrinth, Sagittarion Valley, and Sagittarion Temple. Players can clear new quests in Snowfield Area and begin new adventures to find the lost Princess Cheonpa.

Max. character Level has been increased to 180. The Max. level for Constitution has also been increased to 19, and Inner Force to 18. Upon reaching Lv. 180, characters will be able to obtain 'Level Reward Coffer' which contains 'Mystic Mystical Piece Summon Box', 'Epic Divine Dragon's Enhancement Stone', and more, as well as 'Legendary Blue Dragon Statue'.

The first Party Leader Spirit, Small White Dragon Chunryu, has also been added. The spirit's effects are applied to all nearby party members when a character that this spirit summoned becomes the party leader.

http://mrem.bernama.com/viewsm.php?idm=45302

JUNIPER RESEARCH: REMOTE PATIENT MONITORING USERS TO REACH 115 MILLION GLOBALLY BY 2027; DRIVEN BY HEALTHCARE SYSTEM PRESSURES

BASINGSTOKE, England, Jan 16 (Bernama-BUSINESS WIRE) -- A new Juniper Research study found the total number of patients using RPM (Remote Patient Monitoring) solutions will reach 115.5 million globally by 2027, equating to 1.4% of the total population. This is an increase from only 75 million in 2023. This growth of 67% is driven by greater pressure on healthcare systems, including clinical staff shortages and limited space within hospitals, driving the need for alternative healthcare solutions. RPM enables care to be moved outside of overstressed healthcare facilities; boosting healthcare providers’ efficiency.

RPM solutions encompass a variety of health monitoring devices which enable continuous communication between patients and healthcare providers without the need for close contact.
 

·  To find out more see the new report: Remote Patient Monitoring: Key Trends, Regional Analysis & Market Forecasts 2023-2027 

·  Download the free whitepaper: Remote Patient Monitoring: Three Key Trends in 2023  

Prevalence of Cardiac Conditions to Drive RPM Usage

The research predicted that by 2027, there will be 90 million cardiac patients using RPM solutions. Given the high global prevalence of cardiac conditions, the report recommended that healthcare providers use RPM solutions to monitor the heart rate and blood pressure of cardiac patients at home to lower the number of patients in hospital. RPM solutions will also indirectly decrease disease transmission rates and alleviate pressure on healthcare systems by reducing the demand for hospital beds.

Research author Cara Malone remarked: “There are a variety of connected devices that can be used for cardiac patient monitoring, for example blood pressure and heart rate monitors, which can be challenging for less technologically literate patients. Vendors must prioritise device simplification through software improvements, whilst also incorporating patient education to improve healthcare outcomes.”

AI Analysis Key to Real-time Data Monitoring

The report urged healthcare service providers to fully leverage data generated by the increase in adoption of RPM devices. To maximise the benefits, it recommended that RPM services fully incorporate AI within their solutions to enable healthcare professionals to improve the efficiency of medical triage processes through a predictive proactive healthcare provision model. 

http://mrem.bernama.com/viewsm.php?idm=45218

FREEDOMPAY, ELO INK PARTNERSHIP FOR DIGITAL IN-STORE EXPERIENCE TRANSFORMATION

KUALA LUMPUR, Jan 17 (Bernama) -- FreedomPay, the global leader in Next Level Commerce and Elo, a global provider of interactive solutions and interactive display solutions, announced the integration of Elo’s M60 Pay handheld computer with FreedomPay’s secure commerce technology.

“The partnership with Elo will give customers the secure and seamless checkout experience expected with FreedomPay coupled with the innovative and modular designed solutions from Elo,” said FreedomPay founder and chief executive officer (CEO), Tom Durovsik.

Meanwhile, Elo CEO, Craig Witsoe said the partnership with FreedomPay would bring enhanced functionality and security to create a more personalised experience for consumers.

Built to accept today’s popular payment and loyalty cards, the M60 Pay has a built-in Europay, MasterCard and Visa (EMV), magnetic stripe reader and near-field communication (NFC) for cards with either chips or strips and digital contactless payments.

The Android-based M60 Pay computer can transform from a mobile to a fixed point of sales (POS) solution with the optional docking station, expansion module and Elo touchscreen monitor, said FreedomPay in a statement.

FreedomPay and Elo are reinventing the digital in-store experience by uniting Elo’s innovative and interactive solutions with FreedomPay’s industry-leading commerce technology platform to create a secure, frictionless, unified shopping experience for global consumers while supporting merchants with robust loyalty and data analytics capabilities.

FreedomPay’s Next Level Commerce platform offers many benefits to merchants and customers, including the ability to unify commerce across properties, channels and regions within a single open, fully agnostic, flexible platform.

Other benefits from the platform also consist of a touchless ecosystem that supports contactless payments, QR technology, Apple Pay and Google Pay; and a fully integrated end-to-end solution enabling secure payments, identity-as-a-service, loyalty and business intelligence.

-- BERNAMA

BARCELONA TO FACE REAL MADRID IN FINAL OF SPANISH SUPER CUP

 

Barcelona to face Real Madrid in final of Spanish Super Cup (Photo: AETOSWire) 

RIYADH, Saudi Arabia, Jan 16 (Bernama-BUSINESS WIRE) -- Barcelona made a spectacular victory over Real Betis after 2-2 draw and over penalties, at King Fahd International Stadium in Riyadh yesterday, in the second semi-final of the Spanish Super Cup. A tournament which is brought by the Ministry of Sport for the third consecutive time as part of the sporting events during the 2^nd Diriyah Season.
 

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230113005153/en/ 

In front of a huge number of football fans, Barcelona was able to achieve the precious victory. This win earned Barcelona a place in the final match against Real Madrid that will be held next Sunday 15^th January at 10:00pm Riyadh time in the same stadium.

The Kingdom’s hosting of this major event comes as part of many international sporting tournaments and events taking place in the 2022 Diriyah Season which are brought by the Ministry of Sport, with the aim to achieve the goals of the Kingdom’s Vision 2030, and as one of the “Quality of Life” Program’s initiatives, by hosting the most spectacular and largest international sporting events, to ensure a great experience for the visitors of the Diriyah Season through amazing activities.

http://mrem.bernama.com/viewsm.php?idm=45220

ZENAS BIOPHARMA ANNOUNCES FIRST PATIENT DOSED IN PHASE 3 CLINICAL STUDY OF OBEXELIMAB FOR THE TREATMENT OF IMMUNOGLOBULIN G4-RELATED DISEASE (IGG4-RD)

Global Phase 3 INDIGO study will evaluate the efficacy and safety of obexelimab in patients with IgG4-RD, a chronic and serious fibroinflammatory disease typically affecting multiple organs

IgG4-RD is the first of several potential disease indications to be pursued for obexelimab given its unique non-depleting, B-cell inhibition

WALTHAM, Mass., Jan 12 (Bernama-GLOBE NEWSWIRE) -- Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies, today announced that the first patient has been dosed in the INDIGO Phase 3 registrational study of obexelimab. The INDIGO study will evaluate the clinical efficacy and safety of obexelimab treatment in the prevention of IgG4-related disease (IgG4-RD) flare. Obexelimab is a high-affinity bifunctional antibody that inhibits B-cell lineages by simultaneously binding to CD19 and Fc_үRIIB, thereby downregulating B-cell activity in patients with autoimmune diseases associated with autoantibodies, such as IgG4-RD.

“IgG4-RD is a chronic and serious fibroinflammatory condition that can affect nearly any organ system and can have a profound impact on many patients, leading to severe organ damage or death,” said Hua Mu, M.D., Ph.D., Chief Executive Officer at Zenas. “There are no currently approved treatments for patients living with IgG4-RD. Based upon the promising data from a Phase 2 study of obexelimab in IgG4-RD patients, we are excited to continue to evaluate the potential of obexelimab in the INDIGO study.”

About the INDIGO Study

The INDIGO study is a global multicenter, randomized, double-blind, placebo-controlled study enrolling up to 200 adults with active IgG4-RD signs/symptoms (i.e., flare) that require steroid therapy. Patients will be randomized in a ratio of 1:1 to receive either obexelimab or placebo, administered as subcutaneous injections.

The primary endpoint of INDIGO is time to first IgG4-RD flare (defined as the reappearance of previous signs/symptoms or appearance of new signs/symptoms of IgG4-RD) that requires initiation of rescue therapy from randomization to Week 52. Safety will be evaluated throughout the study duration.

More information on the INDIGO study (NCT05662241) is available at clinicaltrials.gov.

About Obexelimab

Obexelimab is an investigational Phase 3-stage, novel bifunctional antibody with first-in-class potential that inhibits B-cell lineages that express CD19. Simultaneous binding to CD19 and Fc_үRIIB by obexelimab mimics a natural antigen-antibody complex and downregulates B cell activity. In several early-stage clinical studies, 198 subjects were treated with obexelimab. In these clinical studies, the molecule demonstrated effective inhibition of B cell function without depleting the cells and generated an encouraging treatment effect in patients with multiple autoimmune diseases. Zenas acquired exclusive worldwide rights to obexelimab from Xencor, Inc.

About IgG4-RD

IgG4-RD is a chronic and serious fibroinflammatory disease typically affecting multiple organs (e.g., pancreas, liver, kidney, bile duct, salivary and lacrimal glands). Approximately 20,000 people are diagnosed with IgG4-RD in the US, with similar prevalence rates across geographies. Many patients have some degree of irreversible organ damage at the time of diagnosis. Although nearly all patients initially respond to glucocorticoid (GC) therapy, a majority of patients will relapse/flare within a few months of discontinuing treatment, requiring rescue therapy. Chronic GC therapy is also associated with toxicity in many patients.

About Zenas BioPharma

Zenas BioPharma is a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies for patients around the world. With clinical development and operations globally, Zenas is advancing a deep and balanced global portfolio of potential first- and best-in-class autoimmune therapeutics in areas of high unmet medical need while meeting the value requirements of the dynamic global healthcare environment. The company’s pipeline continues to grow through our successful business development strategy. Our experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of those living with autoimmune and rare diseases. For more information about Zenas BioPharma, please visit www.zenasbio.com and follow us on Twitter at @ZenasBioPharma and LinkedIn. 

Investor and Media Contact:
Joe Farmer, President & COO
Zenas BioPharma
IR@zenasbio.com 

SOURCE: Zenas BioPharma (USA) LLC

--BERNAMA 

RIMKUS ANNOUNCES CHIEF EXECUTIVE OFFICER TRANSITION PLANS

Global firm announces leadership update as it reaches 40^th anniversary milestone in 2023

HOUSTON, Jan 10 (Bernama-BUSINESS WIRE) -- Rimkus, a worldwide provider of engineering and technical consulting services, today announced strategic updates to the company’s senior leadership team. After more than 25 years at Rimkus, Robert “Bob” Kocher has retired as President and Chief Executive Officer and assumed a new role as Vice Chair on the Board of Directors. Succeeding Kocher as President and Chief Executive Officer is Jonathan E. Higgins, who previously served as Chief Operating Officer.

This press release features multimedia. View the full release here: 
https://www.businesswire.com/news/home/20230109005050/en/

 

“We are incredibly grateful to Bob for his 25+ years of service to our company, and his vision and leadership these past five years as President and CEO – guiding our business and people through a global pandemic, completing 15 acquisitions, and evolving our service offering into an integrated solution for our clients,” said Curtis Brown, Chairman and Executive Director, Rimkus. “As we approach our 40^th anniversary, it’s an exciting time to welcome new leadership. We have full confidence that Jon will drive our business forward during this next chapter. He is a proven operating executive and a strong champion of our workplace culture.”

Higgins is a graduate of the University of Arizona with a Bachelor of Science degree in Civil Engineering, with an emphasis in structural engineering. Following university, he was commissioned in the U.S. Navy where he served as a Civil Engineering Corps officer. Today, Jon has over 27 years of engineering and leadership experience, drawing on the foundation and core values developed during his military service. He will play a pivotal role in executing the global firm’s strategic plan and solidifying Rimkus’ market position in forensic consulting, dispute resolution and construction management services, solutions for the built environment, and life sciences support for the consumer, industrial, and healthcare industries.

“I’m grateful to Curtis, Bob, and the Board for their confidence and support as I assume this new role,” said Jonathan Higgins, President and Chief Executive Officer, Rimkus. “Having worked at Rimkus for more than 20 years, I am passionate about our people’s success, our commitment to help solve our clients’ most complex problems, and our vision to be a global one-stop resource for our partners. It’s an exciting time in our industry, and Rimkus’ depth and breadth of experience put us in great position to be very successful.”

About Rimkus

Rimkus is a worldwide provider of engineering and technical consulting to corporations, insurance companies, law firms, and government agencies. Rimkus experts specialize in forensic consulting, dispute resolution and construction management services, solutions for the built environment, and human factors support for the consumer, industrial, and healthcare industries. For almost 40 years, the company’s professional engineers, architects, scientists, and technical specialists have been recognized for their commitment to service excellence by local, national, and international business communities. Rimkus operates more than 110 offices worldwide. For more information, visit http://www.rimkus.com. 

http://mrem.bernama.com/viewsm.php?idm=45177

TAIWAN'S NEXT BANK LAUNCHES ON TEMENOS

New digital bank backed by Chunghwa Telecom launches on Temenos core banking platform to bring products to market fast and scale efficiently

GENEVA, Jan 5 (Bernama-GLOBE NEWSWIRE) -- Temenos (SIX: TEMN) today announced that Next Commercial Bank (Next Bank), a new digital bank backed by Chunghwa Telecom, Taiwan’s largest telecom operator, has gone live on Temenos core banking platform, opening to customers during 2022.

One of the first digital banks in Taiwan to receive a virtual banking license from the island’s Financial Supervisory Commission (FSC), Next Bank is building a bank that makes financial management simple with innovative thinking, design aesthetics and friendly experiences.

On Temenos open platform, Next Bank can bring products to market fast and scale efficiently. Today, the digital bank offers deposits, cards, loans and an innovative points program giving customers cashback on purchases, all accessible via a mobile app. Customers can open an account in just three minutes and choose their bank account number, creating a unique and personalized experience.

Over time, the bank plans to introduce foreign-exchange services, including remittance services for migrant workers and wealth management tools. Powered by Temenos, Next Bank aims to rapidly expand to nearly 300,000 customers within nine months of its opening.

Temenos core banking underpins the bank’s entire operations. Built on microservices and accessible via APIs, it enables continuous innovation and delivery for Next Bank to innovate fast and scale its business quickly and sustainably.

Eric Lee, Chief Information Officer, Next Bank, said: “We are excited to launch Next Bank on the Temenos platform. Next Bank operates under the principle of inclusive financing, which aims to provide consumers with universal access to a wide range of financial services. With Temenos, we were able to efficiently build the bank with innovative features that will help customers take charge of their finances and enable us to scale our business and accelerate growth in the future.”

Craig Bennett, Managing Director - Asia Pacific, Temenos, said: “I’m delighted to see Next Bank go live on Temenos, the platform of choice for more than 70 challenger banks worldwide. As one of the first neobanks in Taiwan, Next Bank is already setting a new standard for digital banking in the market. Temenos open platform will empower Next Bank to continue to thrive in the world of instant, always-on services, breaking boundaries to deliver the future of banking today. We are proud to partner with them on this exciting journey to power new growth opportunities and deliver the ultimate customer experience.”

About Temenos
Temenos (SIX: TEMN) is the world’s leading open platform for composable banking, creating opportunities for over 1.2 billion people around the world every day. We serve over 3000 banks from the largest to challengers and community banks in 150+ countries by helping them build new banking services and state-of-the-art customer experiences. The Temenos open platform helps our top-performing clients achieve return on equity three times the industry average and cost-to-income ratios half the industry average.

For more information, please visit www.temenos.com. 

http://mrem.bernama.com/viewsm.php?idm=45152